My Pitch: "$MYOV near term catalysts 3 Phase trials. This quarter they will release top line data from the only ph 3 they need to validate Relugolix for prostate cancer treatment. "

My Pitch: "What can I say, I have owned this from around the $8.00 area in Mid April. I follow Sumitomo Corporation who have a large position in MYOV, when they buy I usually follow. I believe the stock will go to $40 or $50 when the get their Prostate drug Relugolix approved."